G
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
Price:
29.33
CNY
1.31%
Market Cap:
¥12.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
G
|
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
|
CN |
|
P
|
Pricer AB
STO:PRIC B
|
SE |
Income Statement
Earnings Waterfall
Guangdong Taienkang Pharmaceutical Co Ltd
Guangdong Taienkang Pharmaceutical Co Ltd
Income Statement
Guangdong Taienkang Pharmaceutical Co Ltd
Guangdong Taienkang Pharmaceutical Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
5
|
4
|
4
|
3
|
3
|
2
|
1
|
1
|
2
|
3
|
5
|
7
|
9
|
9
|
0
|
0
|
|
| Revenue |
654
N/A
|
697
+7%
|
712
+2%
|
759
+7%
|
783
+3%
|
794
+1%
|
814
+2%
|
791
-3%
|
761
-4%
|
756
-1%
|
751
-1%
|
752
+0%
|
721
-4%
|
717
-1%
|
673
-6%
|
674
+0%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
(319)
|
(314)
|
(328)
|
(340)
|
(328)
|
(338)
|
(326)
|
(312)
|
(303)
|
(311)
|
(313)
|
(312)
|
(318)
|
(323)
|
(329)
|
(334)
|
|
| Gross Profit |
335
N/A
|
382
+14%
|
384
+0%
|
419
+9%
|
455
+9%
|
456
+0%
|
488
+7%
|
479
-2%
|
458
-5%
|
446
-3%
|
438
-2%
|
440
+0%
|
403
-8%
|
393
-2%
|
343
-13%
|
340
-1%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(193)
|
(191)
|
(219)
|
(228)
|
(259)
|
(271)
|
(261)
|
(271)
|
(274)
|
(272)
|
(282)
|
(287)
|
(294)
|
(298)
|
(303)
|
(340)
|
|
| Selling, General & Administrative |
(171)
|
(172)
|
(198)
|
(202)
|
(212)
|
(225)
|
(210)
|
(212)
|
(199)
|
(207)
|
(207)
|
(208)
|
(194)
|
(215)
|
(226)
|
(264)
|
|
| Research & Development |
(23)
|
(25)
|
(25)
|
(29)
|
(35)
|
(50)
|
(57)
|
(64)
|
(57)
|
(64)
|
(71)
|
(75)
|
(79)
|
(85)
|
(81)
|
(79)
|
|
| Depreciation & Amortization |
(14)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(24)
|
0
|
0
|
0
|
(28)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
14
|
6
|
3
|
4
|
5
|
4
|
5
|
5
|
6
|
(2)
|
(4)
|
(3)
|
7
|
1
|
4
|
3
|
|
| Operating Income |
142
N/A
|
192
+35%
|
164
-14%
|
191
+16%
|
196
+3%
|
186
-6%
|
227
+22%
|
208
-8%
|
183
-12%
|
173
-6%
|
156
-10%
|
153
-2%
|
109
-29%
|
95
-12%
|
40
-58%
|
0
-99%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(3)
|
(3)
|
(1)
|
4
|
13
|
19
|
22
|
21
|
15
|
10
|
4
|
1
|
(0)
|
(3)
|
(4)
|
(5)
|
|
| Non-Reccuring Items |
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(2)
|
0
|
0
|
(2)
|
0
|
(1)
|
(1)
|
2
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
|
| Pre-Tax Income |
138
N/A
|
186
+35%
|
163
-12%
|
196
+20%
|
207
+6%
|
205
-1%
|
249
+21%
|
229
-8%
|
192
-16%
|
181
-6%
|
157
-13%
|
152
-3%
|
106
-31%
|
89
-15%
|
34
-62%
|
(7)
N/A
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(18)
|
(29)
|
(23)
|
(28)
|
(33)
|
(33)
|
(45)
|
(44)
|
(39)
|
(37)
|
(32)
|
(31)
|
(9)
|
(4)
|
17
|
21
|
|
| Income from Continuing Operations |
120
|
157
|
140
|
168
|
175
|
172
|
204
|
185
|
154
|
144
|
125
|
121
|
97
|
85
|
50
|
14
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
7
|
9
|
12
|
13
|
11
|
9
|
9
|
9
|
|
| Net Income (Common) |
120
N/A
|
157
+30%
|
140
-10%
|
168
+20%
|
175
+4%
|
173
-1%
|
206
+19%
|
189
-8%
|
160
-15%
|
154
-4%
|
137
-11%
|
135
-2%
|
108
-20%
|
94
-13%
|
60
-37%
|
23
-61%
|
|
| EPS (Diluted) |
0.28
N/A
|
0.66
+136%
|
0.59
-11%
|
0.39
-34%
|
0.41
+5%
|
0.4
-2%
|
0.48
+20%
|
0.44
-8%
|
0.38
-14%
|
0.36
-5%
|
0.32
-11%
|
0.32
N/A
|
0.26
-19%
|
0.22
-15%
|
0.13
-41%
|
0.05
-62%
|
|
Switch to:
Switch to:
See Also
Discover More
